1 Safe-and-Steady Stock on Our Watchlist and 2 to Keep Off Your Radar
Luckily for you, StockStory helps you navigate which companies are truly worth holding. Keeping that in mind, here is one low-volatility stock providing safe-and-steady growth and two that may not deliver the returns you need.
Rolling One-Year Beta: 0.91
Founded in 1919, Hilton Worldwide (NYSE:HLT) is a global hospitality company with a portfolio of hotel brands.
Why Does HLT Worry Us?
Annual sales growth of 4.3% over the last five years lagged behind its consumer discretionary peers as its large revenue base made it difficult to generate incremental demand
Revenue per room has disappointed over the past two years due to weaker trends in its daily rates and occupancy levels
Estimated sales growth of 6.8% for the next 12 months implies demand will slow from its two-year trend
Hilton's stock price of $273.42 implies a valuation ratio of 33.5x forward P/E. If you're considering HLT for your portfolio, see our FREE research report to learn more.
Rolling One-Year Beta: 0.73
Originally founded in 1906 as a thermostat company, Honeywell (NASDAQ:HON) is a multinational conglomerate known for its aerospace systems, building technologies, performance materials, and safety and productivity solutions.
Why Does HON Give Us Pause?
Organic revenue growth fell short of our benchmarks over the past two years and implies it may need to improve its products, pricing, or go-to-market strategy
Earnings growth over the last five years fell short of the peer group average as its EPS only increased by 3.5% annually
Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 3.2 percentage points
At $240.12 per share, Honeywell trades at 22.6x forward P/E. Read our free research report to see why you should think twice about including HON in your portfolio, it's free.
Rolling One-Year Beta: 0.68
Pioneering the "Find, Fight and Follow" approach to disease management, Lantheus Holdings (NASDAQGM:LNTH) develops and commercializes radiopharmaceuticals and other imaging agents that help healthcare professionals detect, diagnose, and treat diseases.
Why Do We Like LNTH?
Annual revenue growth of 34.3% over the last five years was superb and indicates its market share increased during this cycle
Free cash flow margin expanded by 29.5 percentage points over the last five years, providing additional flexibility for investments and share buybacks/dividends
Rising returns on capital show management is finding more attractive investment opportunities
Lantheus is trading at $80.41 per share, or 11.2x forward P/E. Is now the right time to buy? Find out in our full research report, it's free.
Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.
While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
HPMT Holdings Berhad (KLSE:HPMT) Has Some Difficulty Using Its Capital Effectively
What financial metrics can indicate to us that a company is maturing or even in decline? More often than not, we'll see a declining return on capital employed (ROCE) and a declining amount of capital employed. Trends like this ultimately mean the business is reducing its investments and also earning less on what it has invested. And from a first read, things don't look too good at HPMT Holdings Berhad (KLSE:HPMT), so let's see why. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Return On Capital Employed (ROCE): What Is It? For those that aren't sure what ROCE is, it measures the amount of pre-tax profits a company can generate from the capital employed in its business. The formula for this calculation on HPMT Holdings Berhad is: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) 0.033 = RM5.3m ÷ (RM171m - RM12m) (Based on the trailing twelve months to March 2025). Therefore, HPMT Holdings Berhad has an ROCE of 3.3%. In absolute terms, that's a low return and it also under-performs the Machinery industry average of 8.0%. See our latest analysis for HPMT Holdings Berhad Historical performance is a great place to start when researching a stock so above you can see the gauge for HPMT Holdings Berhad's ROCE against it's prior returns. If you're interested in investigating HPMT Holdings Berhad's past further, check out this free graph covering HPMT Holdings Berhad's past earnings, revenue and cash flow. So How Is HPMT Holdings Berhad's ROCE Trending? There is reason to be cautious about HPMT Holdings Berhad, given the returns are trending downwards. About five years ago, returns on capital were 5.5%, however they're now substantially lower than that as we saw above. And on the capital employed front, the business is utilizing roughly the same amount of capital as it was back then. This combination can be indicative of a mature business that still has areas to deploy capital, but the returns received aren't as high due potentially to new competition or smaller margins. So because these trends aren't typically conducive to creating a multi-bagger, we wouldn't hold our breath on HPMT Holdings Berhad becoming one if things continue as they have. The Key Takeaway In the end, the trend of lower returns on the same amount of capital isn't typically an indication that we're looking at a growth stock. It should come as no surprise then that the stock has fallen 30% over the last five years, so it looks like investors are recognizing these changes. Unless there is a shift to a more positive trajectory in these metrics, we would look elsewhere. If you want to know some of the risks facing HPMT Holdings Berhad we've found 3 warning signs (1 is potentially serious!) that you should be aware of before investing here. While HPMT Holdings Berhad may not currently earn the highest returns, we've compiled a list of companies that currently earn more than 25% return on equity. Check out this free list here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
28 minutes ago
- Yahoo
Medpace (MEDP) Q2 Earnings Report Preview: What To Look For
Clinical research company Medpace Holdings (NASDAQ:MEDP) will be reporting results this Monday after market hours. Here's what to expect. Medpace beat analysts' revenue expectations by 6% last quarter, reporting revenues of $558.6 million, up 9.3% year on year. It was an exceptional quarter for the company, with an impressive beat of analysts' organic revenue estimates and an impressive beat of analysts' EPS estimates. Is Medpace a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Medpace's revenue to grow 2.6% year on year to $542 million, slowing from the 14.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $3.00 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Medpace has missed Wall Street's revenue estimates five times over the last two years. With Medpace being the first among its peers to report earnings this season, we don't have anywhere else to look to get a hint at how this quarter will unravel for life sciences tools & services stocks. However, the whole sector has been hit hard over the last month as stocks in Medpace's peer group are down 2.5% on average. Medpace's stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $301.61 (compared to the current share price of $311.86). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio
Yahoo
28 minutes ago
- Yahoo
Earnings To Watch: W. R. Berkley (WRB) Reports Q2 Results Tomorrow
Property casualty insurer W. R. Berkley (NYSE:WRB) will be announcing earnings results this Monday after market close. Here's what to look for. W. R. Berkley met analysts' revenue expectations last quarter, reporting revenues of $3.55 billion, up 8.9% year on year. It was a slower quarter for the company, with a significant miss of analysts' book value per share estimates and EPS in line with analysts' estimates. Is W. R. Berkley a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting W. R. Berkley's revenue to grow 9.7% year on year to $3.63 billion, in line with the 10.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.02 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. W. R. Berkley has missed Wall Street's revenue estimates three times over the last two years. Looking at W. R. Berkley's peers in the insurance segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Progressive delivered year-on-year revenue growth of 21.3%, beating analysts' expectations by 1.4%, and Travelers reported revenues up 7.4%, in line with consensus estimates. Progressive traded up 2.2% following the results while Travelers was also up 5.5%. Read our full analysis of Progressive's results here and Travelers's results here. Investors in the insurance segment have had fairly steady hands going into earnings, with share prices down 1.7% on average over the last month. W. R. Berkley is down 6.8% during the same time and is heading into earnings with an average analyst price target of $71.50 (compared to the current share price of $68.75). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
